# Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC

> **NCT00452881** · PHASE2 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 151 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00452881
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-05
- **Primary completion:** 2009-10
- **Final completion:** 2014-12
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2010-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00452881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00452881, "Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT00452881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*